MedTrace Logo

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

NCT01963728 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-07-26

Study results available
· View outcomes & findings →

Summary

To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).

Conditions

Interventions

DRUG

Insulin, Isophane

daily dosing based on fasting morning glucose levels

DRUG

insulin glargine

daily dose based on fasting morning glucose levels

Sponsors & Collaborators

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Peter Ross, MD · Inova Healthcare Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-27
Primary Completion
2015-04-09
Completion
2015-04-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01963728 on ClinicalTrials.gov